Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archopht.124.6.908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Neurophysiology & Behaviour Lab, University of Castilla-La Mancha, Ciudad Real, Spain.
Background: A key neuropathological feature in the early stages of Alzheimer's disease (AD) involves hippocampal dysfunction arising from the accumulation of amyloid-β (Aβ). Previously, our laboratory identified a shift in the synaptic plasticity long term potentiation (LTP)/long term depression (LTD) induction threshold, leading to memory deficits in a non-transgenic murine model of early AD generated by intracerebroventricular (icv.) injections Aβ oligomers (oAβ), one of the most predominant pathogenetic factors in initial stages of the disease.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Lund University, Lund, Sweden.
Background: Fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer's disease (AD). However, as we recently showed, the overall proteome average in CSF exhibits a non-disease related average signal (inter-individual variability), which can reduce the precision of concentration based CSF AD biomarkers. Now, we therefore investigate if several already high performing CSF and plasma AD biomarkers can be improved by normalizing their concentration to a reference protein (e.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South).
Background: Plasma biomarkers for Alzheimer's disease (AD) have demonstrated their accuracy as diagnostic tools, suggesting their impending integration into clinical practice. Medical comorbidities might not only affect AD pathological burdens but also cause variability of plasma biomarkers by affecting their transfer via blood brain barriers. In the present study, we aimed to determine which comorbidities might affect plasma biomarkers with (real effects) or without (biological variability) AD pathological burdens measured by β-amyloid (Aβ) uptakes on PET.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.
Background: The present study aimed to establish a panel of plasma proteins that are associated with cognitive performance and amyloid-β burden and establish their utility for distinguishing early Alzheimer's disease (AD) from healthy controls.
Method: Plasma from fifty patients with early AD (all amyloid-positive) and forty-nine healthy controls (HCs) were assayed using quantitative mass spectrometry. The weighted correlation network analysis (WGCNA) was used to explore the association between plasma protein levels and cognitive performance and filter out the high-performance plasma proteomic biomarker candidates.
Biomarkers.
Alzheimers Dement
December 2024
Boston University Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Background: Traumatic encephalopathy syndrome (TES) is the proposed clinical syndrome of the neurodegenerative disease chronic traumatic encephalopathy (CTE). As part of the 2021 TES NINDS consensus diagnostic criteria, certainty levels of underlying CTE neuropathology can be determined (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!